ReviewACS omega2026
The Application of Photodynamics Therapy and Tumor Tracing by IR820-Based Nanoparticles Targeting Cancer Cells.
Review in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IR820 is a molecule that emits intense fluorescence in the near-infrared (750-1700 nm) region and can efficiently absorb near-infrared light, converting it into thermal energy, making it powerful in tumor photothermal therapy. However, the nonspecific biodistribution of free IR820 in vivo and the limited tissue penetration depth of light reduce its overall therapeutic efficacy, highlighting the need for further optimization strategies. To address this problem, researchers have engineered IR820 with various nanomaterials to construct nanoplatforms that enable targeted delivery to tumor cells. This review summarizes the applications of IR820-based nanoplatforms in cancer photothermal and photodynamic therapies, with a particular focus on their therapeutic advantages and the current challenges.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.